Dr. Paul Peter Tak @paulpetertak Twitter profile

Last Seen Profiles

@ArelyJesen27938

@luftnovax

@salmonoid_77

@bokeplokalmalam

@gumi93chan

@noe_plexic

@_youngshiner_n1

@SwimmingDuke

@penyukastw21

@ayeaya520

@excell305

@ppomodolii

@StephNebehay

@EconAmericas

@NevaresSalli

@jandakembangstw

@korn0tto

@BoyarskLacey

@palaco_shan

@kiwi29091965

@sosophielia

@tatangagelo

@eduuccm

@FedieKel

@MEFISTO_PORN

@windygirl86

@nf_sigure

@mit_nati

@130yasuno

@ethereum

@DSU_Baseball_

@elijahc77912824

@MargaritaR12638

@Diana__B483

@OnlyfanM

@marcelaramirez

Dr. Paul Peter Tak

@paulpetertak

6 years

A quick personal update: I have stepped down from my previous roles as SVP R&D Pipeline, Chief Immunology Officer and Development Lead at GSK to become Venture Partner at Flagship Pioneering. Very excited by the new opportunity!

8

63

Dr. Paul Peter Tak

@paulpetertak

5 months

Posting comments about the interpretation of clinical trial data comes with a responsibility to get it absolutely right, especially as it relates to cancer patients who are urgently waiting for better treatments. Let's dissect why this post was misleading. A thread.

Ohad Hammer

@ohadhammer

5 months

$CADL's data set has multiple red flags: -OS without a control arm is meaningless, the term "improved survival" in the PR is misleading - No objective responses - Evaluable population is 60% of enrolled patients (and we know the other 40% did much worse because ITT OS is lower)

9

5

41

5

13

48

Dr. Paul Peter Tak

@paulpetertak

6 years

I am excited to announce that I have joined Kintai Therapeutics. Their significant discoveries in just two years since inception are a testament to the remarkable team that I now have the privilege of working with towards our goal of bringing revolutionary medicines to patients.

1

8

43

Dr. Paul Peter Tak

@paulpetertak

2 years

@ParryHotter96 @visegrad24 Better to be a role model

0

40

Dr. Paul Peter Tak

@paulpetertak

4 months

‘The whole idea of CAR-T is becoming a failed theory’. Seriously? Frankly, no expert in the field would be surprised if the discovery and development of CAR-T cell therapies would ultimately be rewarded with a Nobel Prize. It’s been a scientific breakthrough without any doubt.

Biotech2k

@Biotech2k1

4 months

I am going to make a radical statement, but it is now true. 90% of companies in the cell therapy space are a waste of time and money to even invest in. The whole idea of CAR-T is becoming a failed theory. The data has been disappointing over and over again.

8

3

63

6

3

34

Dr. Paul Peter Tak

@paulpetertak

7 months

What a week for $CADL..

Paul Peter Tak, MD PhD FMedSci on LinkedIn: Candel Therapeutics Announces Positive Interim Data...

What a week.. Thank you all for your support and numerous heartwarming reactions! Candel has 6 catalysts this year, 6 shots on goal. The first one went into…

www.linkedin.com

3

29

Dr. Paul Peter Tak

@paulpetertak

6 years

Boston evening

1

0

26

Dr. Paul Peter Tak

@paulpetertak

4 months

Thank you for the questions; happy to address them. 1. Good news, you don't need to wait 5 years! In April 2024, we already presented overall survival (OS) data based on a randomized phase 2A clinical trial of CAN-2409 in pancreatic cancer: median OS (mOS) was 28.8 months in the

Biotechdruganalyst

@Jul05310473John

4 months

@paulpetertak $CADL ok then, now have to wait 5 years to figure out if your drug worked? Where is your ORR data as monotherapy? CADL& $pdsb refuse to run studies with control arm, so no one can actually interpret the data

1

0

1

4

28

Dr. Paul Peter Tak

@paulpetertak

7 months

More exciting news from Candel. We have been working for years to get to this point where we have 6 important inflection points, all in one year. Today: late-breaking presentation at AACR. $CADL #CandelTherapeutics

Candel reveals new TLS candidate at AACR | Paul Peter Tak, MD PhD FMedSci posted on the topic |...

More exciting news from Candel. We have been working for years to get to this point where we have 6 important inflection points, all in one year. First, the… | 10 comments on LinkedIn

www.linkedin.com

5

3

27

Dr. Paul Peter Tak

@paulpetertak

5 months

More encouraging news from Candel Therapeutics: CAN-3110 has now also received Orphan Drug Designation, further highlighting the potential of this therapy for patients with recurrent high-grade glioma. #viral #immunotherapy #CAN -3110 #glioblastoma $CADL

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the...

www.globenewswire.com

1

4

27

Dr. Paul Peter Tak

@paulpetertak

6 months

Today we announce that Candel Therapeutics received FDA Orphan Drug Designation for CAN-2409 for the treatment of pancreatic cancer. The FDA has granted Candel with both Orphan Drug and Fast Track Designation, as we seek to reshape the treatment paradigm in this disease. $CADL

0

4

25

Dr. Paul Peter Tak

@paulpetertak

6 years

The PRAIRI study has been published: first experimental evidence for a preventive window of opportunity in rheumatoid arthritis. Up to a new paradigm of much earlier intervention. Big thank you to the study participants and my colleagues! #

1

9

26

Dr. Paul Peter Tak

@paulpetertak

2 months

We are on track for topline data from our fully enrolled phase 3 (intermediate/high-risk; n=711) and phase 2b (low/intermediate risk, active surveillance population; n=187) randomized controlled clinical trials in early, localized prostate cancer in Q4 2024. #viral #immunotherapy

Candel Therapeutics

@CandelTx

2 months

It is estimated that there will be approx. 299k new cases of #prostatecancer cases in the United States in 2024. At $CADL, we're advancing our viral immunotherapy, CAN-2409, designed to empower the immune system to fight cancer, including #prostatecancer more effectively.

0

2

7

1

2

25

Dr. Paul Peter Tak

@paulpetertak

4 years

Real world evidence that vaccines work: first scone in > 1 year at The Orchard (Granchester)

3

0

23

Dr. Paul Peter Tak

@paulpetertak

4 years

Really?

5

3

24

Dr. Paul Peter Tak

@paulpetertak

2 years

Great to be back in San Diego, my old residence, for #BIO . I hope to see many of you at the meeting.

3

1

24

Dr. Paul Peter Tak

@paulpetertak

5 years

Let’s learn from the countries that did a better job, and not lose another single day. #COVID19

2

14

21

Dr. Paul Peter Tak

@paulpetertak

5 months

The most objective and meaningful response is overall survival. Every other endpoint, such DCR, ORR, and PFS is meant as potential surrogate marker of overall survival. This is what matters most to patients and regulators.

2

0

22

Dr. Paul Peter Tak

@paulpetertak

5 months

As a professor of medicine, I have been Principal Investigator for more than 30 clinical trials, before I became Global Development Leader of GSK and the Chair of GSK's Scientific Review Board. Experience helps to understand what should be achieved in phase 2A clinical trials.

1

0

21

Dr. Paul Peter Tak

@paulpetertak

6 years

This trend of failure in big pharma discovery is expected to continue, unless top scientists with strong leadership skills are supported to change the culture, and foster creativity, collaboration, consistency and rigorous decision making.

Andy Biotech

@AndyBiotech

6 years

Returns on R&D investment for large-cap biopharma hit 9-year low according to new Deloitte report Average cost of bringing a new drug to mkt almost doubled to > $2B, meanwhile forecast peak sales have more than halved since 2010

9

81

150

1

11

21

Dr. Paul Peter Tak

@paulpetertak

4 months

@Biotech2k1 Market cap is a very poor surrogate marker of scientific and clinical success in a dysfunctional market. Financial success lags behind because of poor scientific insight, the impact of ‘the echo chamber’, and more fundamentally the structure of scientific revolutions (Thomas S.

4

2

20

Dr. Paul Peter Tak

@paulpetertak

6 months

Two Candel abstracts accepted at ASCO: 1. Data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma (glioblastoma). 2. Topline overall survival data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer. $CADL

3

20

Dr. Paul Peter Tak

@paulpetertak

2 months

Candel Therapeutics develops CAN-3110, a second-generation herpes simplex virus engineered for replication in tumor cells, for the treatment of recurrent high-grade glioma (glioblastoma). Results based on experimental treatment of the first 41 patients with a single injection of

DocWire News

@mydocwire

2 months

🆕 DocWire News spoke with Dr. @paulpetertak , President & CEO of Candel Therapeutics, to learn more about the company, its treatment pipeline, and how CAN-3110 may offer hope to patients with #glioblastoma . #oncology #neurology @CandelTx 📺 Watch Now:

0

4

1

3

20

Dr. Paul Peter Tak

@paulpetertak

6 years

I had a wonderful experience today. I was not able to buy a bottle of wine at #Target in Cambridge MA today! Both a Dutch Identity Card and a Dutch driving licence were not sufficient to convince the cassier that my 21st birthday happened a few years ago. Very young again!

0

20

Dr. Paul Peter Tak

@paulpetertak

5 months

Prolonged survival after CAN-2409 treatment in NSCLC: for more context see post below.

Paul Peter Tak, MD PhD FMedSci on LinkedIn: Candel Therapeutics Reports Prolonged Overall Survival...

We are very pleased to announce that Candel Therapeutics reports prolonged overall survival in phase 2 clinical trial of CAN-2409 for advanced Non-Small Cell… | 17 comments on LinkedIn

www.linkedin.com

1

8

20

Dr. Paul Peter Tak

@paulpetertak

7 months

Breaking news from Candel Therapeutics: Improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in borderline resectable pancreatic ductal adenocarcinoma.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of...

Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409...

www.globenewswire.com

0

4

20

Dr. Paul Peter Tak

@paulpetertak

2 years

Proud father announcing new M.D.: Dr. Willemijn Tak

Paul Peter Tak, MD PhD FMedSci on LinkedIn: Proud father announcing new M.D.: Dr. Willemijn Tak |...

Proud father announcing new M.D.: Dr. Willemijn Tak | 84 comments on LinkedIn

www.linkedin.com

3

1

19

Dr. Paul Peter Tak

@paulpetertak

6 months

Longwood Healthcare Leaders Conference

0

19

Dr. Paul Peter Tak

@paulpetertak

5 months

Think of it, in 70% of the patients with progressive tumor growth despite optimal standard of care, we could stop the tumors from growing. More importantly, many of these patients lived much longer than would be expected. The long tail of survival you would hope for.

2

0

18

Dr. Paul Peter Tak

@paulpetertak

2 years

@zerohedge So many smart and amazing people in the US. It should be possible to find better candidates to become #president of the USA across both political parties? #POTUS

6

0

15

Dr. Paul Peter Tak

@paulpetertak

10 months

Happy new year!!!

1

0

18

Dr. Paul Peter Tak

@paulpetertak

5 months

Finally, CAN-2409 is not an oncolytic virus. It's a virus designed for in situ vaccination against the patient's injected and uninjected tumors. The strong immunological biomarker data are consistent with its mechanism of action. Off-the-shelf product, individualized response.

1

0

16

Dr. Paul Peter Tak

@paulpetertak

7 months

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate: Tomorrow! #CandelTherapeutics $CADL #viral #immunotherapy #solid #tumor #cancer

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New...

NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical...

www.globenewswire.com

1

4

16

Dr. Paul Peter Tak

@paulpetertak

4 years

You always need to consider you may be wrong. More: ‘seeking out experts who disagree with you and weighing the strength of logic and evidence’ please.

2

5

16

Dr. Paul Peter Tak

@paulpetertak

6 months

Looking forward to sharing our data based on clinical trials of CAN-2409 in solid tumors today!

Therapeutic Cancer Vaccines | 23-24 April 2024 | London, UK & Online

www.immuno-oncologyeurope.com

1

16

Dr. Paul Peter Tak

@paulpetertak

5 months

Because, unfortunately, patients with progressive, metastatic cancer despite chemotherapy and immune checkpoint inhibitor treatment do not exhibit placebo responses or regression to the mean. They die despite standard of care docetaxel chemotherapy.

1

0

15

Dr. Paul Peter Tak

@paulpetertak

4 months

Candel Therapeutics to Join Russell 3000® Index #CandelTherapeutics #Russell3000 $CADL

Candel Therapeutics to Join Russell 3000® Index

NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical...

www.globenewswire.com

1

16

Dr. Paul Peter Tak

@paulpetertak

5 months

See also: Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease (Luke JJ et al. J Immunother Cancer 2024;12:e008378).

1

0

15

Dr. Paul Peter Tak

@paulpetertak

1 year

"The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man." — George Bernard Shaw

Angelos Georgakis

@angelosgeo

1 year

Biotech leaders who want to revolutionize drug discovery and create new modalities: 🧬💊 This is the quote @JMaraganore closed his fireside chat with at Ginkgo Ferment last week. Put this quote on your wall and live by it every single day. I understand that it may be

4

13

95

0

3

15

Dr. Paul Peter Tak

@paulpetertak

4 years

Risk of blood clots. #COVID19 #AstraZeneca #Thrombosis #Vaccine

0

5

14

Dr. Paul Peter Tak

@paulpetertak

4 years

#lastnormalphoto Last dinner with our 4 children all in the same country.

1

0

13

Dr. Paul Peter Tak

@paulpetertak

6 years

My first whale watching at Cape Cod: great big shark arrives for huge breakfast

0

1

14

Dr. Paul Peter Tak

@paulpetertak

2 years

@drkeithsiau One immune-mediated inflammatory disease doesn’t exclude another one - in fact increases the chances of having another one. Could be dactylitis/arthritis and nail abnormalities in psoriasis.

1

14

Dr. Paul Peter Tak

@paulpetertak

5 months

Candel Therapeutics, Inc. (Nasdaq: CADL) will present a company overview at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 5, 2024 at 5:30 p.m. ET. Hope to see you there!

0

3

14

Dr. Paul Peter Tak

@paulpetertak

5 months

#CandelTherapeutics #viral #immunotherapy #CAN -2409 #lungcancer #NSCLC #ASCO $CADL

2

0

13

Dr. Paul Peter Tak

@paulpetertak

2 years

@WNLOpZondag @robdewijk Met Rob de Wijk kun je geen oorlog winnen, dus in die zin is het een logische uitspraak. @ReneJanV

1

0

12

Dr. Paul Peter Tak

@paulpetertak

5 months

It's entirely appropriate to conduct an open label phase 2A trial in therapy-resistant cancer, and much better than going straight from phase 1 to a randomized phase 3 clinical trial. Positive results of an open label clinical trial in this population are meaningful. Why?

1

0

12

Dr. Paul Peter Tak

@paulpetertak

2 years

@durimessikaka @ValaAfshar Same in Dutch: zeehond (= sea dog)

1

12

Dr. Paul Peter Tak

@paulpetertak

4 months

The interesting thing is that the check-the-boxers are often more interested in the surrogate endpoints than the endpoint that really matters to patients and regulators: improved survival with a good quality of life.

Vinay Prasad MD MPH

@VPrasadMDMPH

4 months

Less than half of cancer drugs approved based on a surrogate endpoint are ever found to improve survival in their entire lifecycle.

22

173

579

1

2

13

Dr. Paul Peter Tak

@paulpetertak

5 months

I am supported by a world-class leadership team with decades of experience in drug development. Our Research Advisory Board, which is close to our programs, reads like the who-is-who in immuno-oncology.

2

0

12

Dr. Paul Peter Tak

@paulpetertak

7 months

And first-in-class

Rouleur Capital

@RouleurCapital

7 months

It’s looking like Candel Therapeutics has created a best in class cancer treatment, now effective across multiple cancers. What a breakthrough! Congratulations @CandelTx $CADL

0

2

9

0

4

13

Dr. Paul Peter Tak

@paulpetertak

3 years

Sunset in Norfolk, England after an exciting week getting Candel’s IPO done at Nasdaq

2

0

11

Dr. Paul Peter Tak

@paulpetertak

1 year

It’s an honour to serve this team and its critical mission!

Candel Therapeutics

@CandelTx

1 year

Congratulations to President and CEO, @paulpetertak , MD, PhD, FMedSci, for being named 1 of 30 influential leaders in biopharma on the @medicine_maker Power List 2023! We’re proud to have your guidance and leadership!

1

2

0

11

Dr. Paul Peter Tak

@paulpetertak

3 years

It’s an honour. Thank you to all who helped me to get to this point. #PharmaVOICE100

Candel Therapeutics

@CandelTx

3 years

We're proud to announce our CEO @PaulPeterTak is a recipient of this year’s @PharmaVOICE 100! This annual award celebrates those in the life-sciences industry whose approach to addressing challenges inspires colleagues & peers. Learn more here:

0

4

3

0

12

Dr. Paul Peter Tak

@paulpetertak

1 year

Candel Therapeutics Unveils Groundbreaking Viral Immunotherapies for Solid Tumors - Best Stocks

Dow Jones Today: August 02, 2024

On Friday, the Dow Jones Industrial Average surged by 228.03 points, marking a 0.55% gain and closing at a new

beststocks.com

0

4

10

Dr. Paul Peter Tak

@paulpetertak

5 months

Phase 2A clinical trials are designed to explore efficacy and learn about optimal regimen and protocol, which will inform phase 2B/3. Therefore, the per protocol population is appropriate and consistent with the statistical plan. It allowed us to show the long tail of survival.

1

0

11

Dr. Paul Peter Tak

@paulpetertak

5 years

Welcome to Kintai Therapeutics’s new CBO!

1

2

12

Dr. Paul Peter Tak

@paulpetertak

5 months

We have previously presented encouraging DCR and ORR data in this therapy-resistant population, and now confirm ORR of 8% and DCR (disease control rate) in 70% of the NSCLC patients with progressive disease despite ICI treatment at enrollment.

2

0

11

Dr. Paul Peter Tak

@paulpetertak

10 months

The field of in situ vaccination against solid tumors is maturing. We expect updated overall survival data for CAN-2409 in pancreatic cancer in Q2 (fast track designation), top line overall survival data for CAN-2409 in NSCLC in Q2 (fast track designation)

FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

www.onclive.com

2

1

12

Dr. Paul Peter Tak

@paulpetertak

4 months

Thank you, Melane Sampson, for taking the time to discuss Candel’s viral immunotherapies. $CADL #CandelTherapeutics #viral #immunotherapy #vaccination #solid #tumor #cancer

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherap...

Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat...

biotuesdays.com

0

3

12

Dr. Paul Peter Tak

@paulpetertak

6 months

Another successful example of the effects of viral immunotherapies in solid tumors, the new frontier in immunotherapy for cancer. Congratulations, CG Oncology! #viral #immunotherapy #solid #tumor #cancer ⁦ @cgoncology ⁩ ⁦ @CandelTx ⁩

CG Oncology's BOND-003 study on viral immunotherapies | Paul Peter Tak, MD PhD FMedSci posted on...

Congratulations, CG Oncology, on the updated results of the Phase 3 BOND-003 study, evaluating cretostimogene grenadenorepvec monotherapy for patients with…

www.linkedin.com

1

12

Dr. Paul Peter Tak

@paulpetertak

1 year

Doubling of expected median overall survival in recurrent high-grade glioma after single CAN-3110 injection. @EAChiocca #CandelTherapeutics #CAN -3110 #glioblastoma #BrainCancer #viral #immunotherapy $CADL

E. Antonio Chiocca, MD, PhD, FAANS

@EAChiocca

1 year

Honored to be featured this evening on @WCVB NewsCenter 5 at 6, highlighting our teams’ advances on treating #Glioblastoma . 📸🧠

3

21

133

1

2

12

Dr. Paul Peter Tak

@paulpetertak

2 months

Please join us at the British Society for Immunology meeting on 25-26 Nov 2024 in Cambridge, England. @britsocimm @CandelTx #viral #immunotherapy #cancer #immunology #ImmuneTherapies24

British Society for Immunology

@britsocimm

2 months

Book your place for our BSI #ImmuneTherapies24 ! 🔗 This summit will bring together sector leaders from across #ImmuneTherapies research to discuss challenges & advances in the field 💡 We will also welcome Dr @paulpetertak for an inspiring keynote 🌟

0

2

1

2

12

Dr. Paul Peter Tak

@paulpetertak

2 years

It takes time before a new modality starts to transform the lives of patients and results in significant value creation. Oncolytic viral immunotherapy is at the tipping point and can be expected to create significant value based on recent data in mice and men.

Paras Sharma

@paras_biotech

2 years

Disruptive Innovation takes time to inflect (as presented by mAb dev path)

4

66

356

0

1

12

Dr. Paul Peter Tak

@paulpetertak

2 years

@BRAINCURES @Nature @KevinJTraceyMD It works: Proc Natl Acad Sci U S A, 2016;113:8284-9 Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis Koopman, FA et al.

1

4

12

Dr. Paul Peter Tak

@paulpetertak

3 years

We are proposing a radical new approach to immune-mediated inflammatory disease, moving the field from one that is based on clinical signs and symptoms to one that is based on immunological and molecular mechanisms.

0

2

12

Dr. Paul Peter Tak

@paulpetertak

6 years

My birthday party end of 2018: great experience to explore new horizons outside my comfort zone. Happy new year everybody!

0

11

Dr. Paul Peter Tak

@paulpetertak

1 year

@gloefflmann @HeleneBismarck Unlike in Europe, a professor is usually address as ‘Doctor’ in the US. The film is correct in this respect.

1

0

10

Dr. Paul Peter Tak

@paulpetertak

3 years

Great dinner speech by Dr Siddharta Mukherjee at Accelerating Bio-Innovation: we will increasingly see ‘reverse in-licensing’, from South to North. @CambridgeATS ⁦ @RoyaltyPharma ⁩ ⁦ @ideapharma ⁩ #accbioinno2022

2

10

Dr. Paul Peter Tak

@paulpetertak

5 months

More succes stories from the viral immunotherapy field. Congratulations!

CG Oncology, Inc.

@cgoncology

5 months

👏 We're excited to share the publication of the final results of our CORE-001 Phase 2 trial of cretostimogene in combination w/pembrolizumab are available in @NatureMedicine . Co-authored by @UrogerliMD , this study advances treatment options for #NMIBC .

0

3

18

1

11

Dr. Paul Peter Tak

@paulpetertak

3 years

#Omicron variant of #SARS_CoV2 : if a virus mutates significantly, resulting in higher transmissibility, it may have become less lethal. This would be the best outcome for humans AND the virus. We’ll find out in the next few weeks. #COVID19

2

0

11

Dr. Paul Peter Tak

@paulpetertak

1 year

Beautiful Amsterdam

1

0

11

Dr. Paul Peter Tak

@paulpetertak

8 months

CAN-3110 has received FDA Fast Track Designation for the treatment of recurrent high-grade glioma, a significant milestone in the development of this innovative viral immunotherapy. According to data published in Nature, CAN-3110 has shown a strong anti-tumoral response. $CADL

0

6

9

Dr. Paul Peter Tak

@paulpetertak

1 year

This amazing @CandelTx team develops viral immunotherapies for patients with cancer. They look relaxed here, knowing that a lot of data based on our clinical trials will come out in the next several weeks to months. #immunotherapy #cancer #viral #vaccination #solidtumor

Candel Therapeutics

@CandelTx

1 year

#FlashbackFriday to last week’s summer celebration. After months of hard work, we took the well-earned time to celebrate summer with #Candoers at our annual summer party.

0

1

6

1

2

11

Dr. Paul Peter Tak

@paulpetertak

4 years

It’s a great pleasure to announce that during the summer I have joined Candel Therapeutics as its CEO. We will work relentlessly to develop novel viral oncolytic immunotherapies for patients with cancer. #Oncolyticvirus #cancer #candeltherapeutics

3

0

11

Dr. Paul Peter Tak

@paulpetertak

4 years

This is exactly how modern drug discovery should be organised to drive optimal innovation and decision making.

Medicxi

@medicxi

4 years

Excited to announce the launch of Centessa Pharmaceuticals! A next generation pharma company founded by @medicxi to improve R&D productivity by delivering asset-centricity at scale. Led by CEO Saurabh Saha and CSO Moncef Slaoui

1

17

38

0

5

11

Dr. Paul Peter Tak

@paulpetertak

7 months

It is possible to improve these success rates: optimize therapeutic target selection; focus on the quality of the therapeutic molecule; use early, high-density-of-data experimental medicine clinical trials to inform go/no go decisions; use good judgement based on data.

Rami Rahal

@ratatat79

7 months

J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched. #AACR24 “Path to Entrepreneurship” session

5

30

141

1

3

11

Dr. Paul Peter Tak

@paulpetertak

3 years

Successful academics do not necessary leave academia because ‘there is a problem’ in academia, but because they may have a bigger impact and learn new skills elsewhere.

Marcus Munafò

@MarcusMunafo

3 years

Chris is the fourth person I know and have worked with to leave academia in the last four months - all people with "permanent" faculty positions. Small pebbles presaging a serious problem in academia?

4

24

74

1

4

11

Dr. Paul Peter Tak

@paulpetertak

5 months

Thank you, Arthur Franken, Nathalie ter Wengel, Kathereh Ahmadi, George Schragel and Nerida Scott for a great panel discussion about deal making at #BioEquity in San Sebastian! ⁦ @CandelTx ⁩

0

10

Dr. Paul Peter Tak

@paulpetertak

5 months

@FcRnMabs @ohadhammer There’s no response more objective and meaningful than survival. See my LinkedIn post for more context.

1

10

Dr. Paul Peter Tak

@paulpetertak

2 years

Agreed. Candel Therapeutics presented data on its virtual R&D Day (Dec 6) showing disease control in 77% of patients with progressive NSCLC during ICI treatment after administration of CAN-2409 (in situ vaccination). There was a decrease in size of uninjected tumor in 67%. $CADL

Brad Loncar

@bradloncar

2 years

Great to see ‘cancer vaccine’ and ‘good news’ used in the same sentence. Using vaccines as therapeutics against metastatic disease for so long in the past was the dark ages. Playing a role like adjuvant use and other earlier settings leverages a naturally stronger immune system.

11

3

40

0

2

10

Dr. Paul Peter Tak

@paulpetertak

4 years

Leadership without bossy, controlling behaviours is critical to foster a culture of innovation and creativity and to help people get the best out of themselves. #leadership

1

4

10

Dr. Paul Peter Tak

@paulpetertak

4 months

Easy. N Engl J Med, 2024 vol. 390(8) pp. 687-700. ‘CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.’ Major development in immune-mediated inflammatory diseases.

Biotech2k

@Biotech2k1

4 months

@paulpetertak @drrichjlaw Name me 1 good CAR-T data read out in the last 5 years? They are all massive disappintmnets.

1

0

1

2

0

10

Dr. Paul Peter Tak

@paulpetertak

6 years

UK government pushing for the same failed Brexit deal reminds me of Monty Python’s genius Black Knight

1

2

8

Dr. Paul Peter Tak

@paulpetertak

5 months

Interesting illustration of what you may find, developing successful immunotherapies for solid tumors: improved overall survival in the absence of Overall Response Rates (a surrogate marker that was not developed for the evaluation of immunotherapies)

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma - PubMed

This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded...

pubmed.ncbi.nlm.nih.gov

0

1

10

Dr. Paul Peter Tak

@paulpetertak

7 months

We continue to make great progress with the development of CAN-3110 for recurrent high-grade glioma (glioblastoma). #viral #immunotherapy #glioblastoma $CADL

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit...

The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting toxici...

finance.yahoo.com

0

3

10

Dr. Paul Peter Tak

@paulpetertak

3 years

Excellent collaboration between Brigham & Women's Hospital, Harvard Medical School, University Hospital Tuebingen, and Candel Therapeutics. #glioblastoma #braintumor #cancer #oncolytic #virus #CandelTherapeutics #CAN -2409

This link will take you to a page that’s not on LinkedIn

lnkd.in

1

2

9

Dr. Paul Peter Tak

@paulpetertak

7 months

HSV-1 does work beyond the skin: Nature, 2023 vol. 623(7985) pp. 157-166. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. $CADL

Biotech2k

@Biotech2k1

7 months

$KRYS is a company using HSV-1 to delivery gene therapies. I know this management well as I was in early for this company and owned it on and off for years. I love what they are doing in skin, but I have doubts if HSV-1 works beyond the skin. I have it on my list already.

1

0

7

0

3

10

Dr. Paul Peter Tak

@paulpetertak

2 years

@modernstrategy_ @FitFounder Coffee does not cloud the mind and at the right ‘dose’ it may result in health benefits.

0

10

Dr. Paul Peter Tak

@paulpetertak

3 years

It’s a great pleasure to support BIOS Health’ amazing journey: Creating the programming language for lifelong health! #BIOSHealth

0

1

10

Dr. Paul Peter Tak

@paulpetertak

2 years

Really happy that our hypothesis published in 2009 has been confirmed. Several companies, including @SetPointMed and @GalvaniBioelec1 , are pursuing bioelectronic stimulation of the cholinergic anti-inflammatory pathway as a new treatment for rheumatoid arthritis.

Krzysztof Potempa

@BRAINCURES

2 years

In a 2009 @NatRevRheumatol review, @paulpetertak 's team proposed that it may be possible to stimulate the anti-inflammatory pathway using small molecules to activate the alpha-7 receptor or a bioelectronic approach using electrical stimulation of the vagus

1

0

1

0

2

10

Dr. Paul Peter Tak

@paulpetertak

6 years

Be led by curiosity and science

0

5

10

Dr. Paul Peter Tak

@paulpetertak

6 years

Seen in London on the day the 2018 #NobelPrize in Physiology or Medicine has been awarded to James P. Allison and Tasuku Honjo

0

2

10

Dr. Paul Peter Tak

@paulpetertak

3 years

12h later.. beautiful start of the new year.

0

9

Dr. Paul Peter Tak

@paulpetertak

3 years

The relationship between problems and solutions in different countries. Do you recognise it?

0

2

10

Dr. Paul Peter Tak

@paulpetertak

5 years

3 weeks ago I posted about the possibility that hydroxychloroquine could perhaps work in covid-19. Since then: not learned anything meaningful from clinical trials/experience and political noise. We need proper randomized, controlled trials urgently! #COVID19 #Hydroxychloroquine

Dr. Paul Peter Tak

@paulpetertak

5 years

There are many interesting new studies like: "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" (via #pubmedontap )

2

3

9

1

0

9

Dr. Paul Peter Tak

@paulpetertak

7 months

The new frontier in cancer immunotherapy: educating the patient’s immune system how to recognize and eliminate tumor cells. #CandelTherapeutics

nature

@Nature

7 months

After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment

16

199

681

0

1

9

Dr. Paul Peter Tak

@paulpetertak

6 years

Bill Gates expects a breakthrough based on microbiome-related research of the gut

Microbial Biotherapeutics

The Opportunity Recent research has demonstrated that the clinical outcomes of undernutrition in infants are associated with gut dysfunction as well as altered gut microbiota with reduced diversity...

gcgh.grandchallenges.org

0

3

9

Dr. Paul Peter Tak

@paulpetertak

2 years

‘To simplicity, to freedom, and to life’ - beautiful speech. @CarolynBertozzi @NobelPrize

The Nobel Prize

@NobelPrize

2 years

"Chemists are dreamers. We think up new molecules and bring them to life." Listen to chemistry laureate Carolyn Bertozzi's speech from this evening's #NobelPrize banquet, where she described how this year's chemistry achievements have made the previously impossible reality.

35

423

1K

0

3

8

Dr. Paul Peter Tak

@paulpetertak

3 years

Great to be back in person to discuss the latest opportunities in the biomedical field.

0

1

9